Physician profile
Michael V Keiley
NPI 1679569149
$6,904.27
in general payments reported to CMS, 2019-2025
36 companies · $1,501 in 2025
The $1,501 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $417 · 2021: $745 · 2022: $1,020 · 2023: $1,209 · 2024: $1,450 · 2025: $1,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,063 · Education: $84.23 · Consulting Fee: $12.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,063.28 |
| Education | $84.23 |
| Consulting Fee | $12.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,223.05 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $906.07 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $779.38 | 2019-2025 | Dupixent |
| Csl Behring | $679.02 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Grifols USA, LLC | $654.96 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $408.70 | 2020-2025 | Cuvitru, Takhzyro |
| Genentech USA, INC. | $313.91 | 2022-2025 | Xolair |
| Blueprint Medicines Corporation | $284.18 | 2023-2025 | Ayvakit |
| Amgen INC. | $218.53 | 2021-2025 | Tezspire |
| Genzyme Corporation | $207.08 | 2019-2025 | |
| Kaleo, INC. | $161.73 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $155.42 | 2020-2025 | |
| Octapharma USA, INC. | $118.58 | 2020-2023 | Cutaquig |
| Pharming Healthcare, INC. | $97.06 | 2023-2025 | Ruconest |
| Aimmune Therapeutics, INC. | $93.94 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $65.74 | 2025 | Neffy |
| Pfizer INC. | $63.93 | 2020-2024 | |
| Incyte Corporation | $60.58 | 2021-2023 | Opzelura |
| Verona Pharma, INC. | $54.70 | 2025 | Ohtuvayre |
| Biocryst US Sales Co., LLC | $44.71 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.95 | 2021 | |
| Galderma Laboratories, L.P. | $38.25 | 2024-2025 | Nemluvio |
| Tersera Therapeutics LLC | $24.10 | 2024 | Quzyttir |
| Ionis Pharmaceuticals, INC. | $22.21 | 2025 | Dawnzera |
| Organon LLC | $20.79 | 2025 | Vtama |
| Sanofi US Services INC. | $20.75 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $19.11 | 2021 | |
| Mylan Specialty L.P. | $18.71 | 2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $17.30 | 2022 | |
| Abbvie INC. | $17.06 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.62 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $14.58 | 2021 | |
| Circassia INC. | $13.07 | 2019 | |
| Adma Biomanufacturing LLC | $12.74 | 2023 | |
| Sunovion Pharmaceuticals INC. | $11.37 | 2019 | |
| Bio Products Laboratory USA, INC. | $8.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Keiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.